Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-Human Study of YQ23 in Healthy Volunteers
NCT03802292Phase 1Completed
- Sponsor
- New Beta Innovation
- Start
- Jan 2019
- Primary completion
- Sep 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in critical limb ischemia (CLI) and solid tumor comparing Single Ascending Dose YQ23 with Single Dose Placebo (2 arms). Primary endpoints: Incidence of Treatment-emergent Adverse Events (TEAE), Incidence of laboratory abnormalities and 9 more. Started Jan 2019; status: completed.
02
Drugs
YQ23
03
Conditions
critical limb ischemia (CLI)solid tumor
Beyond the preview
Go deeper on NCT03802292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03802292.